Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Chemotherapy-induced anemia (CIA) is a frequent complication of cancer treatment that occurs when chemotherapy damages bone marrow, leading to reduced red blood cell production and impaired oxygen delivery in the body. According to Dana Elkhalifa et al., 2025, epidemiological studies indicate that anemia affects roughly 25% to almost 90% of cancer patients, reflecting its significant clinical burden. Current treatment options include erythropoiesis-stimulating agents, iron therapies, and blood transfusions to manage symptoms. The growing focus on targeted supportive therapies, improved safety outcomes, and personalized care is strengthening drug development efforts. According to the chemotherapy-induced anemia pipeline analysis by Expert Market Research, rising cancer prevalence and therapeutic advancements are expected to drive notable growth in the coming years.
-
Major companies involved in the chemotherapy-induced anemia pipeline analysis include Shenyang Sunshine Pharmaceutical Co., Ltd., Kind Pharmaceuticals LLC, and others.
-
Leading drugs currently in the pipeline include SSS06, AND017, SAL-0951, and others.
-
The strong pipeline growth is driven by novel erythropoiesis-stimulating agents, hypoxia-inducible factor stabilizers, and combination therapies improving hemoglobin response, safety profiles, and patient adherence across oncology treatment settings.
Report Coverage
The Chemotherapy Induced Anemia Pipeline Analysis Report by Expert Market Research provides comprehensive insights into chemotherapy induced anemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chemotherapy induced anemia. The chemotherapy induced anemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chemotherapy induced anemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chemotherapy induced anemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chemotherapy induced anemia.
Read more about this report - Request a Free Sample
Chemotherapy Induced Anemia Pipeline Outlook
Chemotherapy induced anemia is a common complication of cancer treatment caused by chemotherapy damaging bone marrow and reducing red blood cell production. It occurs when cytotoxic drugs suppress erythropoiesis or increase red blood cell destruction, leading to fatigue, weakness, and reduced oxygen delivery throughout the body.
Chemotherapy induced anemia treatment commonly uses erythropoiesis-stimulating agents, iron supplementation, blood transfusions, and supportive therapies aimed at restoring hemoglobin levels and improving oxygen transport in cancer patients. According to Alfredo Tartarone et al., 2023, darbepoetin alfa has demonstrated continued clinical relevance, supported by regulatory approvals for cancer-related anemia. It received United States Food and Drug Administration approval for chemotherapy induced anemia in March 2006, while the European Medicines Agency authorized its use in adult cancer patients in June 2001.
Chemotherapy Induced Anemia Epidemiology
Chemotherapy-Induced Anemia remains a critical unmet need in oncology drug development. According to Dana Elkhalifa et al., 2025, global cancer-related anemia prevalence varied from 12.8% to 100% across 65,179 patients from 40 countries. Higher incidence was reported in lung (84.2%), pediatric (80.9%), gynecological (62.99%), and gastrointestinal cancers (57.4%). Composite anemia prevalence was 64.99% in multiple cancer types and 25.68% in solid tumors. Chemotherapy and radiotherapy significantly increased anemia incidence, with some post-treatment cohorts reaching 100%. Regional disparities were noted, especially in Africa, South America, and the MENA regions. These epidemiological trends underscore active pipeline opportunities.
Chemotherapy Induced Anemia – Pipeline Therapeutic Assessment
This section of the report covers the analysis of chemotherapy induced anemia drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The chemotherapy induced anemia pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Peptides
- Oligonucleotides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Chemotherapy Induced Anemia Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 60% covers a major share of the total chemotherapy induced anemia clinical trials, highlighting strong mid-stage development. Phase I and IV each account for 20%, demonstrating active early and late-stage progress. This balanced distribution across phases indicates robust innovation, potentially accelerating treatment availability and positively impacting the market growth and patient outcomes.
Chemotherapy Induced Anemia Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the chemotherapy induced anemia pipeline analysis include small molecules, peptides, and oligonucleotides. The chemotherapy induced anemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chemotherapy induced anemia. Hypoxia‑inducible factor prolyl hydroxylase (HIF‑PH) inhibitors are a key drug class in the chemotherapy‑induced anemia (CIA) pipeline. For instance, Roxadustat, an oral HIF‑PH inhibitor, is under clinical development to enhance erythropoiesis and improve hemoglobin levels in patients with CIA.
Chemotherapy Induced Anemia Clinical Trials – Key Players
The EMR report for the chemotherapy induced anemia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chemotherapy induced anemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chemotherapy induced anemia clinical trials:
- Shenyang Sunshine Pharmaceutical Co., Ltd.
- Kind Pharmaceuticals LLC
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Kyntra Bio
- Chugai Pharmaceutical
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Ortho Biotech Products, L.P.
- Zydus Lifesciences Limited
- Amgen
- Hoffmann-La Roche
Chemotherapy Induced Anemia – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chemotherapy induced anemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chemotherapy induced anemia drug candidates.
Drug: SSS06
SSS06 is a long-acting, highly glycosylated recombinant erythropoietin-based protein being developed by Shenyang Sunshine Pharmaceutical Co., LTD. for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies. The ongoing Phase II multicenter study is evaluating the safety, tolerability, immunogenicity, pharmacokinetics, and preliminary efficacy of SSS06 injection. The drug is being administered subcutaneously at varying dose levels every three weeks. SSS06 is working by stimulating red blood cell production through erythropoietin receptor activation, aiming to improve hemoglobin levels and reduce anemia-related complications.
Drug: AND017
AND017 is an investigational oral drug being developed by Kind Pharmaceuticals LLC for the treatment of chemotherapy-induced anemia. The Phase 2 multicenter, randomized, open-label study is currently not yet recruiting and is examining the safety and efficacy of AND017 over a six-week treatment period in cancer patients receiving chemotherapy. AND017 is being administered as oral capsules three times weekly across multiple dose groups. The drug is being designed to improve hemoglobin levels by stimulating red blood cell production and supporting oxygen delivery. The study is aiming to evaluate optimal dosing, tolerability, and therapeutic response in anemia management.
Drug: SAL-0951
SAL-0951 (Enarodustat Tablets) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being developed by Shenzhen Salubris Pharmaceuticals Co., Ltd. for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies. The ongoing Phase II multicenter, open-label clinical study is evaluating the safety, efficacy, and optimal dosing of SAL-0951 administered once daily, with dose adjustments based on hemoglobin levels. This phase is aiming to examine the drug’s ability to stimulate endogenous erythropoietin production, improve hemoglobin concentration, and maintain an acceptable safety profile, thereby supporting dose optimization and progression toward future Phase III clinical development.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Chemotherapy Induced Anemia Pipeline Insight Report
- Which companies/institutions are leading the chemotherapy induced anemia drug development?
- Which company is leading the chemotherapy induced anemia pipeline development activities?
- What is the current chemotherapy induced anemia commercial assessment?
- What are the opportunities and challenges present in the chemotherapy induced anemia pipeline landscape?
- What is the efficacy and safety profile of chemotherapy induced anemia pipeline drugs?
- Which company is conducting major trials for chemotherapy induced anemia drugs?
- Which companies/institutions are involved in chemotherapy induced anemia collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in chemotherapy induced anemia?
Reasons To Buy This Report
The Chemotherapy Induced Anemia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chemotherapy induced anemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chemotherapy induced anemia collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share